Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Two Lots of Zoledronic Acid Injection, 5mg/100mL due to Potential Lack of Container Integrity
March 04, 2014 12:04 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., March 4, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of two lots of Zoledronic Acid Injection, 5mg/100mL...
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Results
February 11, 2014 07:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today...
Sagent Pharmaceuticals Launches National Research Center in Chengdu, China
February 03, 2014 08:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Feb. 3, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today...
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2013 Financial Results
January 30, 2014 16:30 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conference
January 08, 2014 08:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Announces the Launch of Octreotide Acetate Injection
December 23, 2013 14:30 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Dec. 23, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Octreotide Acetate Injection, a Somatostatin Analog, in five vial...
Sagent Pharmaceuticals Announces the Launch of Propofol Injectable Emulsion USP 1%
November 18, 2013 08:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Propofol Injectable Emulsion USP 1%, in two Single-Dose, Single-Patient...
Sagent Pharmaceuticals Announces the Launch of Doxorubicin Hydrochloride Injection, USP
November 11, 2013 07:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Nov. 11, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Doxorubicin Hydrochloride Injection, USP, an antineoplastic agent, in three...
DCAT Announces New Board Member
November 07, 2013 13:45 ET
|
Sagent Pharmaceuticals, Inc.
ROBBINSVILLE, N.J., Nov. 7, 2013 (GLOBE NEWSWIRE) -- The Drug, Chemical & Associated Technology Association (DCAT) is pleased to announce that Lori Hoffman, senior director, business development...
Sagent Pharmaceuticals Announces the Launch of Levetiracetam Injection
November 06, 2013 17:03 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Levetiracetam Injection, the generic form of the antiepileptic Keppra®,...